edi200
Recombinant proteinexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2012 (NCT01564225)
Timeline
Indications
Studied for
Mechanism of action
- Ectodysplasin-ASupplementation
EDA supplementation
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- NCATSAF6GZK1UMB ↗
- ChEMBLCHEMBL4297944 ↗
Also known as
- edi200
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01775462 | Phase 2 | Apr 1, 2013 | Edimer Pharmaceuticals |
| NCT01564225 | Phase 1 | May 1, 2012 | Edimer Pharmaceuticals, University of California, San Francisco |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Edimer Pharmaceuticals | For profit | 2 | 2 | 2 | 2012 |
| University of California, San Francisco | Academic/Hospital | 1 | 0 | 1 | 2012 |
2 organizations
Page 1 / 1